A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

In the advanced renal cell carcinoma (RCC) scenario, there are no consistent biomarkers to predict the clinical benefit patients derived from immune checkpoint blockade (ICB). Taking this into consideration, herein, we conducted a retrospective study in order to develop and validate a gene expressio...

Full description

Bibliographic Details
Main Authors: Yoel Z. Betancor, Miriam Ferreiro-Pantín, Urbano Anido-Herranz, Mar Fuentes-Losada, Luis León-Mateos, Silvia Margarita García-Acuña, Vanessa Vaamonde-Rodríguez, Beatriz García-Pinel, Víctor Cebey-López, Rosa Villaverde-Viaño, Helena Lombardía-Rodríguez, Martin Kotrulev, Natalia Fernández-Díaz, Iria Gomez-Tourino, Carlos Fernández-Baltar, Jorge García-González, Jose M. C. Tubio, Rafael López-López, Juan Ruiz-Bañobre
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
nivolumab
biomarker
gene expression
immunotherapy
kidney cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374728/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1374728/full

Similar Items